Neogen Corp
NASDAQ:NEOG

Watchlist Manager
Neogen Corp Logo
Neogen Corp
NASDAQ:NEOG
Watchlist
Price: 9.42 USD
Market Cap: $2.1B

EV/EBITDA

33.9
Current
43%
More Expensive
vs 3-y average of 23.7

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
33.9
=
Enterprise Value
$2.7B
/
EBITDA
$79.1m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
33.9
=
Enterprise Value
$2.7B
/
EBITDA
$79.1m

Valuation Scenarios

Neogen Corp is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (23.7), the stock would be worth $6.59 (30% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-62%
Maximum Upside
No Upside Scenarios
Average Downside
42%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 33.9 $9.42
0%
3-Year Average 23.7 $6.59
-30%
5-Year Average 27.2 $7.55
-20%
Industry Average 12.9 $3.58
-62%
Country Average 14.4 $3.99
-58%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$2.7B
/
Mar 2026
$79.1m
=
33.9
Current
$2.7B
/
May 2026
$174.1m
=
15.4
Forward
$2.7B
/
May 2027
$188.5m
=
14.2
Forward
$2.7B
/
May 2028
$199.3m
=
13.5
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
US
Neogen Corp
NASDAQ:NEOG
2.1B USD 33.9 -3.4
US
Medline Inc
NASDAQ:MDLN
62.4B USD 0 0
JP
Hoya Corp
TSE:7741
9.7T JPY 28.1 38.7
CH
Alcon AG
SIX:ALC
30.1B CHF 14.5 37.7
DK
Coloplast A/S
CSE:COLO B
96.5B DKK 12.7 24
US
Align Technology Inc
NASDAQ:ALGN
13.9B USD 14.8 34
UK
ConvaTec Group PLC
LSE:CTEC
4.5B GBP 11.9 34.3
CA
Bausch + Lomb Corp
NYSE:BLCO
5.7B USD 16.9 -15.7
KR
HLB Inc
KOSDAQ:028300
8.3T KRW -83.8 -37.5
JP
Asahi Intecc Co Ltd
TSE:7747
868.9B JPY 23.2 49.1
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.3B USD 14.6 22.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Neogen Corp
NASDAQ:NEOG
Average EV/EBITDA: 19
33.9
19%
1.8
US
M
Medline Inc
NASDAQ:MDLN
Not Available
9%
N/A
JP
Hoya Corp
TSE:7741
28.1
13%
2.2
CH
Alcon AG
SIX:ALC
14.5
9%
1.6
DK
Coloplast A/S
CSE:COLO B
12.7
6%
2.1
US
Align Technology Inc
NASDAQ:ALGN
14.8
14%
1.1
UK
ConvaTec Group PLC
LSE:CTEC
11.9
11%
1.1
CA
Bausch + Lomb Corp
NYSE:BLCO
16.9
29%
0.6
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -83.8 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
23.2
13%
1.8
US
Lantheus Holdings Inc
NASDAQ:LNTH
14.6
23%
0.6
P/E Multiple
Earnings Growth PEG
US
Neogen Corp
NASDAQ:NEOG
Average P/E: 34.4
Negative Multiple: -3.4
N/A N/A
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.7
15%
2.6
CH
Alcon AG
SIX:ALC
37.7
32%
1.2
DK
Coloplast A/S
CSE:COLO B
24
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
34
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
34.3
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.7 N/A N/A
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -37.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
49.1
40%
1.2
US
Lantheus Holdings Inc
NASDAQ:LNTH
22.8
30%
0.8

Market Distribution

Higher than 81% of companies in the United States of America
Percentile
81st
Based on 9 875 companies
81st percentile
33.9
Low
0 — 10
Typical Range
10 — 21.5
High
21.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 10
Median 14.4
70th Percentile 21.5
Max 1 767 274.1

Neogen Corp
Glance View

Market Cap
2.1B USD
Industry
Health Care

Founded in 1982, Neogen Corp. has steadily carved out its niche at the intersection of food safety and animal health, positioning itself as a vital player in agricultural diagnostics. The company's journey began in Lansing, Michigan, where it initially focused on innovative solutions to meet the growing demands of food safety and quality testing. By developing rapid tests for detecting foodborne bacteria and allergens, Neogen tapped into a critical market, addressing the increasing concerns about food safety amidst a complex global supply chain. This foundation in diagnostics set the stage for the growth Neogen would see over the ensuing decades. As Neogen expanded, it strategically diversified its offerings, moving beyond food safety into the broader realm of animal health. This expansion was not merely about developing products; it was about advancing the means by which farms and food producers monitor and ensure the health of their livestock and crops. The company's profits flow from the sale of its diagnostic products, which help minimize risks associated with food contamination and animal diseases. By providing a suite of solutions, from DNA testing for genetic traits and diseases in cattle to disinfectants and rodenticides that maintain farm hygiene, Neogen creates value for its clients by increasing their operational efficiency and safeguarding public health. This strategic blend of food safety and animal health products places Neogen at the heart of modern agricultural and food production systems, where safety and efficiency are paramount.

NEOG Intrinsic Value
6.71 USD
Overvaluation 29%
Intrinsic Value
Price $9.42
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett